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Elaborate uORF/IRES features control expression
and localization of human glycyl-tRNA synthetase
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Abbreviations: aaRS, aminoacyl-tRNA Synthetase; ER, Endoplasmic Reticulum; GARS, Glycyl-tRNA Synthetase; IRES, Internal
Ribosome Entry Site; MTS, Mitochondrial Targeting Signal; Uorf, upstream Open Reading Frame; UTR, UnTranslated Region
The canonical activity of glycyl-tRNA synthetase (GARS) is to charge glycine onto its cognate tRNAs. However,
outside translation, GARS also participates in many other functions. A single gene encodes both the cytosolic and
mitochondrial forms of GARS but 2 mRNA isoforms were identiﬁed. Using immunolocalization assays, in vitro translation
assays and bicistronic constructs we provide experimental evidence that one of these mRNAs tightly controls
expression and localization of human GARS. An intricate regulatory domain was found in its 50-UTR which displays a
functional Internal Ribosome Entry Site and an upstream Open Reading Frame. Together, these elements hinder the
synthesis of the mitochondrial GARS and target the translation of the cytosolic enzyme to ER-bound ribosomes. This
ﬁnding reveals a complex picture of GARS translation and localization in mammals. In this context, we discuss how
human GARS expression could inﬂuence its moonlighting activities and its involvement in diseases.
Introduction
Human glycyl-tRNA synthetase (GARS) is an essential com-
ponent of the translation apparatus. GARS is ubiquitously
expressed and plays a central role in protein synthesis by catalyz-
ing the attachment of glycine to cognate tRNAs (tRNAs). How-
ever, GARS, like other mammalian aminoacyl-tRNA synthetases
(aaRS) 1-3 is involved in functions beyond translation.4 Most of
these alternative functions were identified mainly through the dis-
covery of several diseases linked to mutations in the correspond-
ing gene or to the presence of antibodies against extracellular
GARS. In humans, at least 13 dominant mutations in the GARS
gene cause motor and sensory axon loss in the peripheral nervous
system and lead to clinical phenotypes ranging from Charcot-
Marie-Tooth (CMT) type 2D neuropathy to a severe infantile
form of spinal muscular atrophy type V.5-10 Though GARS
activity is required in all cells, the CMT-associated mutations
affect only the peripheral nervous system. The links between
GARS mutations, tissue-specificity, and pathological mechanisms
remain unclear (reviewed in).7 Several studies identified autoanti-
bodies to 8 different aaRSs; among them, anti-GARS antibodies
(anti-EJ) are mainly found in patients with inflammatory myopa-
thy, polymyositis and dermatomyositis (reviewed in).11 Yet infor-
mation on their clinical impact is still limited. Interestingly,
GARS autoantibodies were also detected in the sera of patients
with breast cancer.12 GARS is indeed secreted by macrophages
and acts as a cytokine with a distinct role against specific tumor
cells.13 Moreover, GARS binds the Internal Ribosome Entry Site
(IRES) located at the 50-end of the poliovirus RNA genome and
promotes its cap-independent translation initiation.14 Together
these observations suggest that, in mammals, GARS expression
may be regulated in response to many different stimuli.
Three independent reports indicated that a single gene enco-
des both the cytoplasmic and mitochondrial forms of human
GARS.15-17 This is in contrast to other aaRSs for which cyto-
plasmic and mitochondrial tRNA aminoacylation is achieved by
the products of 2 separate genes (the only other exception being
lysyl-tRNA synthetase). The GARS gene was predicted to pro-
duce both cytoplasmic and mitochondrial enzymes via alternative
translational start sites.15 Analysis of fetal liver cDNA encoding
human GARS,16 as well as primer extension experiments on
transfected cells.17 identified a single mRNA characterized by a
long 50-UTR with 5 putative initiation codons (Fig. 1A). Based
on these observations, it was anticipated that the more distal start
codons relative to the transcriptional start site would initiate
translation of the cytosolic GARS, while one or more proximal
codons would initiate the mitochondrial enzyme. In addition,
the presence of 3 other upstream initiation codons could indicate
the existence of some regulatory mechanism(s); for instance one
of these codons would lead to the synthesis of a short upstream
Open Reading Frame (uORF), encoding 47 amino acids and
potentially controlling GARS expression.16
This study focuses on the control of human GARS expression.
Indeed, many aspects of the regulation of this enzyme remain
unclear, especially its tissue specific expression and the control of
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both mitochondrial and cytosolic forms of the enzyme. There-
fore, in this study, different human tissues were used to further
characterize the 5’-UTR of the human GARS mRNA that may
lead to the understanding of the molecular mechanism governing
such regulations. Contrary to previous studies, which identified
one long mRNA with 5 start codons, 2 different mRNA isoforms
containing 2 and 3 start codons respectively were found. These
two GARS mRNAs were present in all tissues and vary only by
the length of their 50-UTRs. They were tested for their respective
capacity to support translation of the mitochondrial and the cyto-
solic GARS, in vitro and in transfected cells. Interestingly, both
50-UTRs behave differently. The longer 50-UTR contains not
only an uORF but also a functional IRES, which directs GARS
translation into the endoplasmic reticulum (ER), strengthening
our prediction of a complex regulatory mechanism.
Results
Identification of 2 mRNA isoforms
Both the human mitochondrial and cytosolic glycyl-tRNA
synthetase (GARS) enzymes are encoded by the same gene
(GARS), located on chromosome 7, and use 2 alternative initia-
tion codons. One mRNA isoform was previously identified from
fetal liver cDNA, showing the presence of a long 50-UTR (357
nucleotides upstream of the putative initiator codon for mito-
chondrial GARS synthesis) containing 3 other potential initia-
tion codons.17 (Fig. 1A). To further explore the presence of
alternative mRNA isoforms in other human tissues, 50- and 30-
RLM-RACE PCR (RNA Ligase Mediated Rapid Amplification
of cDNA Ends PCR, Fig. S1A) were performed on total RNA
from 6 different human tissues: liver, brain, spinal cord, muscle,
heart and spleen. Two populations of mRNAs (mRNA1 and
mRNA2) were present in brain, spinal cord, muscle, heart and
spleen tissues and only one (mRNA2) was found in liver tissue
(Fig. S1B). These two mRNA isoforms contain both initiator
codons corresponding to the predicted translation start sites of
the mitochondrial GARS (AUGmito, at position C1) and of the
cytosolic GARS (AUGcyto, at position C163). mRNA1 and
mRNA2 shared the same 30-UTR sequence (166 nts; data not
shown) and differ only in the length of their 50-UTR (Fig. 1A).
The longest mRNA (mRNA1) was characterized by an 85 nt
long 50-UTR (C/- 6 nts) and contains one extra AUG initiation
codon (AUG0) close to the 5
0-end (position -69). Unlike AUG-
mito and AUGcyto, AUG0 was not in frame with the GARS ORF
and codes for a small uORF. This uORF would potentially initi-
ate the synthesis of a 32 amino acid peptide that ends at a stop
codon (UAG) located 26 nt downstream of AUGmito. The
shorter mRNA, mRNA2, had a very short 50-UTR (between 21
and 29 nt) and displayed only AUGmito and AUGcyto start
codons (Fig. 1A).
Figure 1. Organization of human GARS mRNAs. (A). Schematic represen-
tation of the 2 isoforms of the human GARS mRNA revealed in this study.
The sequence identiﬁed by Mudge and collaborators in 1998 in fetal liver
cells17 was used as a reference. The long mRNA1 contains 3 initiation
codons, AUG0 (initiates the synthesis of the uORF), AUGmito (initiates
translation of the mitochondrial targeting signal -MTS- fused to GARS),
AUGcyto (initiates translation of the cytosolic GARS) and a UAG stop
codon (ends translation of the uORF). The shorter mRNA2 contains only
AUGmito and AUGcyto. (B). Multiple alignment of mammalian mRNA1 50-
UTR: blasting the nucleotide sequence of Homo sapiens GARS mRNA1
(NC_018918.2) against all NCBI nucleotide databases (http://blast.ncbi.
nlm.nih.gov/Blast) retrieved 43 sequences only from other mammalian
genomes. Among them, 14 GARS sequences were from primates. Here,
is shown only a representative selection of the retrieved sequences:
Homo-sapiens (NC_018918.2), Gorilla-gorilla (NC_018431.1), Pan-troglo-
dyte (NC_006474.3), Nomascus-leucogenys (NC_019832.1), Pongo-abelii
(NC_012598.1), Macaca-mulatta (NC_007860.1), Cavia-porcellus
(XM_003467957.2), Pteropus-alecto (XM_006912040.1), Mustela-putorius-
furo (XM_004762573.1), Ceratotherium-simum (XM_004418866.1), Ovis-
aries (XM_004007927.1), Bos-Taurus (NM_001097566.1), Orycteropus-afer
(XM_007945456.1), Odobenus-rosmarus-divergens (XM_004413949.1),
Orcinus-orca (XM_004269943.1), Mus-musculus (NC_000072.6), Rattus-
norvegicus (NC_005103.3) GARS sequences. Sequence alignments were
computed with Tcoffee software (http://igs-server.cnrs-mrs.fr/Tcoffee/
tcoffee_cgi/index.cgi).46 The 3 AUG codons, AUG0, AUGmito and AUGcyto,
are boxed in yellow, the stop codon in red. Absence of these speciﬁc
codons is indicated in gray on the alignment. The schematic representa-
tion of the 50- end of mRNA1, used in this manuscript, is indicated: AUGs
are signaled with circles, the uORF stop codon with a red cross, and the
frameshift deletion with a green bar.
1302 Volume 12 Issue 12RNA Biology
50-RLM-RACE PCR was done again, under the same condi-
tions, but without removing the 50-cap from the mRNAs before
ligation of the 50-adaptor (Fig. S1A). No PCR fragments were
retrieved, indicating that both GARS mRNA1 and mRNA2 are
capped in the cell.
Searching for mRNA1 and mRNA2 in the DataBase of Tran-
scriptional Start Sites.18 (DBTSS, which represents exact posi-
tions of TSSs in the genome) 2 TSSs corresponding to both
GARS mRNA isoforms were found. Based on the number of
reads for each mRNA, relative expressions of mRNA1 and
mRNA2 could be determined. They vary considerably in the dif-
ferent tissues tested (Fig. S2), with in general, more mRNA2
than mRNA1. Only adult testis, lung and brain 1 show more
mRNA1 than mRNA2.
Sequence comparison
The 50-end of the GARS mRNA1 sequence was used to blast
NCBI nucleotide databases. Forty-three sequences were retrieved,
showing that this organization, with 3 ATG codons and one stop
codon, was found only among mammals (Fig. 1B). However, in
the case of the mouse and rat genomes, the GARS DNA sequen-
ces differ by the position of the stop codon, found before AUG-
mito. There are a few other exceptions in the translation potential
of some sequences (not shown on the alignment): pika (Ochotona
princeps), wild boar (Sus scrofa), elephant (Loxodonta Africana)
and dog (Canis lupus familiaris) have the AUG0 in the same open
reading frame as AUGmito and AUGcyto and the dolphin (Lipotes
vexillifer) sequence is missing AUG0, suggesting different regula-
tory mechanisms or hypothetical sequencing mistakes. Besides
mammals, other eukaryotic GARS gene sequences did not align
with the 250 nts found at the 50-end of the GARS mRNA1
sequence.
Characterization of mRNA1 and mRNA2 in translation
DNA constructs encoding mRNA1 and mRNA2 sequences
fused to the V5-tag were transfected in COS-7 cells. In order to
compare the capacity of each mRNA isoform to support GARS
expression and determine its nature (mitochondrial or cytosolic),
Western blot and immunolocalization experiments were per-
formed on transfected cells (Fig. 2). Western blot analysis
(Fig. 2A) showed that both mRNAs produced a unique band
corresponding to the theoretical size of the cytosolic GARS
(approximately 90 kDa). Because the mitochondrial targeting
signal (MTS) (54 amino acids, 5.6 kDa) is removed when the
mitochondrial GARS enzyme is targeted to its final destination,
the resulting mature enzyme cannot be differentiated from the
cytosolic GARS based only on its size. Thus, mRNA1 and
mRNA2 were tested in vitro in wheat germ extract translation
assays (Fig. 2A). In this system, proteins are not matured, thus it
is possible to distinguish the mitochondrial from the cytosolic
GARS based on their respective lengths. Indeed, in the test per-
formed with mRNA2, both the mitochondrial (long) and the
cytosolic (short) GARSs could be detected. However, mRNA1
led only to the synthesis of the cytosolic (short) GARS. Immuno-
localization experiments (Fig. 2B) allowed us to further charac-
terize the products of translation of the 2 mRNAs. In agreement
with the results of in vitro translation experiments, GARS-V5
subcellular localizations showed that the mRNA2 construct leads
to the synthesis of both the mitochondrial and the cytosolic
GARSs. Since the 50UTR sequences are continuous in the
genome, it indicates that both AUGmito and AUGcyto codons
present in this mRNA are used to initiate efficient translation.
However, the longer mRNA1, which contains 3 potential initia-
tion sites, codes for the cytosolic form of the protein only.
Functional characterization of the 3 AUG codons
present in mRNA1
In order to assess if all 3 AUG codons in mRNA1 can initiate
translation, they were mutated and tested. The translation effi-
ciencies of GARS translated from these mRNA1 variants were
determined by Western blot analysis and their subcellular local-
izations were determined by immunolocalization of transfected
COS-7 cells (Fig. 3A, B; Fig. S3). In the absence of the 2 other
AUG codons, initiation at AUG0 (mutant a) did not produce
any visible protein, initiation at AUGmito (mutant b) led to the
synthesis of the mitochondrial GARS and initiation at AUGcyto
Figure 2. Translation of both mRNA isoforms in vivo and in vitro. (A). Top
panel shows Western blot analysis of COS-7 cells transfected with
pcDNA3.1 encoding mRNA1 or mRNA2 fused to a V5 epitope nucleotide
sequence on their 30-ends. Translated GARS-V5 proteins are detected by
anti-V5 antibodies. Detection of the 42 kDa ß-actin (anti-actin antibod-
ies) was included as a loading control. Bottom panel corresponds to
translation of radioactive GARSs from mRNA1 and mRNA2 in vitro,
accomplished using wheat germ extracts. (B). GARS-V5 was detected by
immunoﬂuorescence, using anti-V5 antibodies coupled to FITC (green).
Mitochondria were stained with Mitotracker Orange CMTMRos (red) and
nuclei were stained with DAPI (blue). The ﬁnal localization of GARS is
speciﬁed for each mRNA. For the mRNA1 scheme, please refer to the
end of the Figure 1 legend.
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(mutant c) allowed the synthesis of the cytosolic GARS. Addition
of AUG0 upstream of AUGmito (mutant d), prevented initiation
at AUGmito; yet, AUG0 did not affect translation initiation at
AUGcyto (mutant e). These observations indicated that AUG0
selectively prevents translation of the mitochondrial GARS con-
sistently. Mutation of AUG0 (mutant f) restored translation initi-
ation at AUGmito. Finally, the deletion of nt C at position -45
(Fig. 1B) allowed AUG0 to be in the same reading frame as
AUGmito and AUGcyto (mutant g). Interestingly, this frame-shift
allowed the synthesis of a GARS that was mainly targeted to the
mitochondria, suggesting that in
this mutant, either AUG0 or
AUGmito might be used to initiate
translation.
T7 RNA polymerase tran-
scribed mRNA1 and mRNA2 as
well as mRNA1 mutants (a to g)
were tested for in vitro translation
(Fig. 3C). The results confirmed
what was observed with immuno-
localization experiments: AUG0
alone or with AUGmito did not allow GARS expression (mutants
a and d); removing AUG0 permitted ribosomes to initiate at
AUGmito and AUGcyto (mutant f); and the presence of only
AUGcyto (mutant c) or AUGmito (mutant b) led to the synthesis
of the cytosolic or the mitochondrial GARS, respectively. Lastly,
the frameshift mutation (mutant g) led to the synthesis of an
“extra-long” GARS that corresponds to the addition of 23 extra
amino acids at the N-terminus of the MTS, indicating that initia-
tion takes place only at AUG0. This addition didn’t affect the tar-
geting sequence (Fig. 3A, mutant g). This result clearly shows
Figure 3. Immunolocalization of
GARS expressed from mutated
mRNA1. (A). Six mutants (a to h) were
generated in mRNA1 where the dif-
ferent AUG codons were tested for
translation. GARS-V5, mitochondria
and nuclei detection were performed
as indicated in the legend of Figure 2
and the mRNA1 scheme is described
at the end of the Figure 1 legend.
The ﬁnal localization of GARS is speci-
ﬁed for each mRNA. Corresponding
co-localization statistics are indicated
in Figure S3A. (B). GARS expression
levels (Western blot). Mutant g shows
2 bands (extra-long GARS and cyto-
solic GARS), indicating that the pro-
tein is only partially matured inside
the mitochondria. In mutants a, b, d
and h, all missing AUGcyto, initiation
of a shorter GARS is observed, which
is not detectable in immunolocaliza-
tion experiments. This short form of
the protein is observed only in vitro
and appears when initiation is very
inefﬁcient. It shows (i) that the mRNA
is present in the test and (ii) that the
ribosome scans until it ﬁnds the next
initiator codon. In the speciﬁc case of
mutant h, its expression is so low that
10 times more protein extract was
loaded in hx10 to detect it. Detection
of the 42 kDa ß-actin (anti-actin anti-
bodies) was included as a loading
control. (C). The same mutants were
used in in vitro translation experi-
ments (rabbit reticulocyte extracts) in
the presence of 35S methionine.
Mutant h was not tested in vitro.
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that, despite its close proximity to the 50-end of mRNA1 (3 to 20
nts, Fig. S1B), AUG0 is recognized as an initiation codon and
would thus promote the synthesis of the 32-residue peptide.
Two main differences between in vivo immunolocalization
and in vitro translation results occurred. The wild type mRNA1
product did not show any mitochondrial localization in Fig. 3A,
however in vitro a weak band that corresponded to the mitochon-
drial GARS could be observed. The other difference concerned
mutant e, which was strongly expressed in the cytosol in vivo but
was a poor substrate in vitro. Artifacts, such as mRNA alternative
structures, due to in vitro T7 RNA polymerase transcription,
could explain these discrepancies. Moreover mutation of AUG-
mito might destabilize the structure of the 5
0 end of the in vitro
transcribed RNA, so that the alternative structure does not allow
efficient translation initiation in vitro.
The ribosome reinitiates at the AUG immediately
downstream of the uORF stop codon
In order to test the possibility that ribosomes reinitiate after
synthesis of the uORF, the stop codon initially present between
AUGmito and AUGcyto (mutant d) was moved before AUGmito
(mutant h). Despite reduced efficiency, the mitochondrial GARS
was translated instead of the cytosolic GARS as expected for ribo-
some reinitiation (Fig. 3A-C). Additionally, since construct g
gives rise to only the extra-long GARS (Fig. 3B, C), it implies
that all ribosomes initiate first at the AUG0 with no leaky scan-
ning. It thus also supports that, in wild type mRNA1, AUGcyto is
recognized only by reinitiating ribosomes that have translated the
uORF.
mRNA1 supports cap-independent translation initiation
Taking into account the high percentage of GC (74%) and
our unsuccessful attempts to solve the mRNA1 structure in solu-
tion using chemical and enzymatic methods, it was considered
that mRNA1 would encompass a stable fold. Together with its
unique expression pattern, we hypothesized that the extra RNA
sequence present at the 50-end of mRNA1 would contain an
IRES. In order to test this idea, mRNA1 and mRNA2, each 50-
modified either with the natural m7G cap or with the non-func-
tional Ap3G cap analog were produced. These mRNA transcripts
were subjected to in vitro translation in wheat germ extracts
(Fig. 4A). As expected, translation of m7G capped mRNA1 gen-
erated one major band corresponding to the cytosolic GARS
(about 80%) and translation of m7G-capped mRNA2 led to 2
bands of comparable intensities (55% cytosolic GARS and 45%
mitochondrial GARS). In contrast, when these mRNAs were
capped with the non-functional Ap3G cap analog, mRNA1 was
still translated (>50%) while translation of mRNA2 was
abolished.
To further confirm the ability of mRNA1 to initiate transla-
tion in a cap-independent manner, a stable hairpin structure.19
was inserted at the 50-extremity of both mRNA1 and mRNA2
constructs. Such a structure is expected to hinder ribosome scan-
ning and, as a consequence, cap-dependent initiation.20,21
mRNAs without or with the stable hairpin structure were
expressed for 24 hours in COS-7 cells. The corresponding
Western blot analysis (Fig. 4B) clearly shows that the hairpin
structure indeed inhibited mRNA2 but not mRNA1 translation
confirming the presence of a peculiar initiation site in mRNA1.
Figure 4. Cap-independent versus cap-dependent initiation. (A). In vitro
translation reactions of mRNA1 and mRNA2 were performed with wheat
germ extracts. Both mRNAs were capped either with the natural m7G or
the inhibitor cap analog Ap3G. Synthesized GARSs correspond to the
mitochondrial (upper band) and cytosolic (lower band) enzymes. Expres-
sion levels of cytosolic (dark bars) and mitochondrial (light bars) GARSs
were quantiﬁed relative to the cytosolic GARS translated from mRNA2.
Error bars were calculated from 3 independent experiments. (B). Western
blot analysis: Effect of a strong hairpin structure on GARS expression:
COS-7 cells were transfected with pCDNA3.1 constructs containing a
strong hairpin structure introduced at the 50-end of mRNA1 and mRNA2
(HP mRNA1 and HP mRNA2, respectively).
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mRNA1 contains a functional IRES
To test the presence of a functional IRES in mRNA1, the
bicistronic renilla/firefly luciferase system pRF was used. The
pRF vector contains an SV40 promoter and generates long
mRNAs with 2 consecutive cistrons: the first one is translated in
a cap-dependent manner and codes for the renilla luciferase (R),
whereas the second one codes for the firefly luciferase (F), which
is expressed only if the inserted inter-
cistronic region has a functional
IRES.20
Vectors pRF and pRVcipF (contain-
ing a well-characterized cellular
IRES).22 were used as negative and
positive controls, respectively. The
entirety of mRNA1 (nt -78 to C163,
including AUG0, AUGmito and AUG-
cyto) was cloned in the intercistronic
region (Fig. 5A). COS-7 cells were
then transiently transfected with the 3
constructs and both renilla and firefly
luciferase activities were measured
(Fig. 5B). The relative firefly/renilla
ratio showed strong IRES activity for
pRmRNA1F, 150-fold higher than the
negative control and comparable to
pRVcipF IRES activity (70%).
Several controls were carried out to
exclude any experimental artifacts
(Fig. S4). To rule out the presence of
cryptic promoters, the SV40 promoter
was deleted from the bicistronic vec-
tors, hindering the transcription of
bicistronic mRNAs. As expected, both
renilla and firefly activities were drasti-
cally decreased confirming the absence
of strong cryptic promoters (Fig. S4A).
However, for both pRVcipF and
pRmRNA1F, a residual firefly luciferase
activity (20% and 15%, respectively)
could still be detected, corresponding
to the cryptic promoter activity present
in the firefly liciferase gene.23
Because unwanted splicing could
lead to the production of 2 monocy-
stronic mRNAs instead of the bicis-
tronic mRNA, the synthesis of the
firefly luciferase could be the result of a
cap-dependent initiation. Thus, the
presence of such putative splicing
events was tested: total RNAs, purified
from transfected COS-7 cells, were
subjected to reverse transcription and
PCR amplification. Specific primers
covering the promoter region and part
of the firefly luciferase sequence were
used (Fig. S4B). The results of this
specific RT-PCR reaction showed that a unique product was
amplified corresponding to each pRF construct (the size of
amplified inserts were: 1245 nt, 1815 nt and 1498 nt for pRF,
pRVcipF and pRmRNA1, respectively).
Finally, to eliminate the possibility of ribosome shunting or
read-through of the renilla stop codon, the length of the pro-
duced firefly luciferase protein was verified by Western blot (Fig.
Figure 5. Comparison of mRNA1 and Vcip IRES elements for their ability to initiate translation. (A). Sche-
matic representation of biscistronic pRF constructs: sequences corresponding to the Vcip IRES and
mRNA1 50-end (containing the 3 AUG codons) were inserted in the intercistronic region between the
renilla and ﬁreﬂy ORFs (pRVcipF and pRmRNA1F). The cap structure at the 50-end of the bicistronic mRNA
is indicated with a black circle. (B). pRF, pRVcipF and pRmRNA1F were transfected in COS-7 cells and renilla
(cap dependent initiation) and ﬁreﬂy (IRES-mediated initiation) luciferase activities were measured.
pRVcipF and pRmRNA1F luciferase activities were represented relative to pRF activity. (C). pRF, pRmRNA1F,
pRmouseF and pRVcipF were transfected in COS-7 cells and IRES-mediated initiation were measured.
pRmouseF express the mouse sequence corresponding to mRNA1 (see Fig. 1B). (D). Shorter versions of
the mRNA1 IRES sequence were cloned in pRF and their respective luciferase activities were measured.
Graphic representations of pRmRNA1F, pR mRNA1F deletants and pRmRNA2F activities are relative to the
pRF negative control. Standard deviations were calculated from 3 independent experiments. For the
mRNA1 scheme, please refer to the end of the Figure 1 legend.
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S4C). Whereas no protein was detected either for pRF or the
mock transfections, a unique band of the expected size (62 kDa)
was observed when pRVcipF and pRmRNA1F constructs were
transfected in COS-7 cells, showing that the synthesis of the fire-
fly luciferase is indeed initiated at the expected AUG.
In order to confirm that the IRES function of mRNA1 is also
conserved in other mammals, the mouse 50-UTR, which has the
most divergent sequence (Fig. 1B) was tested using the pRF sys-
tem. The mouse 50-UTR controlled expression of firefly lucifer-
ase with the same efficiency as the human sequence (Fig. 5C).
Looking for control of IRES-dependent expression
Cellular IRESs are often expressed when cap-dependent trans-
lation is inhibited either by stress or under particular physiologi-
cal conditions.24-26 Therefore, several conditions where mRNA1
IRES mediated expression could be affected, were tested.
First, different stress conditions were applied to cells trans-
fected with bicistronic constructs: (i) starvation by omitting the
serum in the medium; (ii) glucose deprivation using a low glu-
cose medium; (iii) mTOR pathway inhibition in the presence of
100 nM Rapamycin; and (iv) hypoxia with the addition of 150
mM CoCl2. Any particular stimulation either with Vcip, or
GARS mRNA1 were observed (data not shown).
Another consideration was the presence of a putative 5 base-
pair sequence (50-152CGGAG156-30) complementarity to the 30-
extremity of 18S rRNA (50-1839UUCCG1843-30). Mutating this
sequence in pRmRNA1F allowed testing if these nucleotides could
stabilize the mRNA on the 40S subunit and facilitate AUG0/
AUGcyto recognition by the ribosome. Again, in this context, the
mutations did not lead to reduction of IRES activity (data not
shown).
Finally, because it has been shown that GARS binds to and
stimulates translation from the poliovirus IRES,14 GARS was
cotransfected with the bicistronic constructs and tested whether
GARS co-expression could modify firefly luciferase synthesis.
Again, this did not alter mRNA1 IRES controlled expression of
firefly luciferase (data not shown).
The mRNA1 GARS product colocalizes with endoplasmic
reticulum associated ribosomes
Contrary to mRNA2, the GARS produced by mRNA1
showed some ambiguous localization (Fig. 2B). Indeed, the
GARS produced from mRNA1 organizes in a network. Thus
additional immunolocalization assays were performed in the
presence of digitonin, in order to extract the soluble cytoplasmic
GARS, leaving behind only the GARS attached to cellular struc-
tures (Fig. 6; Fig. S3B). Colocalization assays between GARS-
V5 and the Mitotracker label confirmed that the GARS trans-
lated from mRNA2 is indeed present in the mitochondria
whereas most of the GARS translated via the mRNA1 IRES is
clearly associated with another cellular structure (compare panels
a and b). To identify the nature of this cellular structure,
mRNA1 and mRNA2 constructs were co-expressed with the Sig-
nal Recognition Particle (SRP) receptor B subunit which is an
integral ER protein (coupled to DsRed: Srprb-DsRed) or with
the endogenous ribosomal protein rm6S. mRNA2 does not show
obvious colocalization with the ER or with ribosomes (panels e
and f), but mRNA1 behaves differently. Indeed, panel c shows
that the GARS network was in close proximity to the ER.
Figure 6. Differential colocalization of GARS with subcellular structures,
depending on mRNA isoforms. GARS-V5 was expressed from mRNA1
(left) or mRNA2 (right). GARS-V5 localizations (green) were compared
with red markers for mitochondria (a and b, Mitotracker), ER protein
(c and d, SRPs-DsRed) and endogenous ribosomal protein S6 (e and f,
rmS6). In order to remove the background noise due to the cytosolic
GARS, transfected COS-7 cells were ﬁrst permeabilized with digitonin.
This treatment strips the plasma membrane, so that cells lose most of
their cytosolic content but retain intact mitochondria and ER. Nuclei
were stained with DAPI (blue). Corresponding co-localization statistics
are indicated in Figure S3B.
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Besides, it superimposed clearly with ribosomes (panel e), sug-
gesting that the mRNA1 product interacts with ER-associated
translating ribosomes. It is known that the large ribosomal sub-
unit is tightly bound to the ER membrane, whereas the
small subunit can freely exchange between soluble and membra-
nebound states.27 Thus, antibodies directed against the small
subunit allowed the detection of actively translating ribosomes
that are bound to the ER. Because transfected genes recruit most
of the translating ribosomes available in the cell, expression of
mRNA1 GARS increased considerably the ER-bound ribosomes
density and confirmed that mRNA1 is translated locally. On the
contrary, the absence of ER-bound ribosomes proved that
mRNA2 is decoded by cytosolic ribosomes, which are washed
away by the digitonin treatment (untransfected neighboring cells
still contain ER-bound translating ribosomes). In this case, only
the mitochondrial GARS is detected.
This observation led us to compare the localization of both
GARS mRNA isoforms by subcellular fractionation experiments
(Fig. S5); Contrary to P450 cytochrome oxidase, which is an
integral ER membrane protein, GARS did not co-purify with the
ER fraction and confirmed that the GARS mRNA1 product dif-
fuses in the cytosol. However, both mRNA1 and mRNA2 were
found attached to the ER fraction, indicating that the localization
signal is present in the ORF sequence.
Insights into mRNA1 IRES structure
We faced technical problems in studying the mRNA1
IRES structure in solution due to intricate and stable IRES
folding that hindered all our attempts to solve its structure.
Thus, bioinformatics tools were used to build a structural
model of the GARS IRES based on sequence alignments with
mammalian 50-UTRs (Fig. S6). The two-dimensional model
shows a 3-way junction linking Watson-Crick helices: (i) the
50- and 30-ends interact together to form a double stranded
domain (helix I) containing both AUG0 and AUGcyto, (ii)
the left arm (helix II) covers most of the uORF and displays
AUGmito and the uORF stop codon, (iii) the right arm (helix
III) corresponds to the rest of the MTS coding region of the
mitochondrial GARS. Such a structure presents strong poten-
tial for tertiary interactions as well as extensive major/minor
groove contacts between helices.28 When the 50 nucleotides
present at the 50-end of mRNA1 were deleted, the firefly
activity decreased to its background activity (Fig. 5D),
whereas progressive shortening at the 30-end of mRNA1 50-
UTR led to progressive losses in IRES activity (Fig. 5D).
Thus, any change in the sequence destabilizes the structure
and affects the IRES initiation and/or reinitiation mecha-
nisms. This clarifies what was observed with the mRNA1
mutants missing AUG0 (mutants b, c and f). In the case of
an exclusive IRES initiation mechanism, these mutants should
be completely inactive in translation. However, because
AUG0 is involved in the structure of helix I, its mutation
could lead to unfolding of this domain and introduce enough
instability so that cap-dependent initiation and ribosome
scanning can occur in vivo and in vitro (Fig. 3).
Discussion
A previous study used primer extension to analyze fetal liver
cDNA encoding human glycyl-tRNA synthetase (GARS) and
identified a single mRNA isoform.16 This mRNA encoded the 2
initiator codons dedicated to the mitochondrial (AUGmito) and
the cytosolic (AUGcyto) forms of the enzyme. The 5
0-UTR was
371 nucleotides long and contained 3 other AUG codons
upstream of AUGmito. However, despite repeated attempts, the
authors were unable to confirm the mRNA TSS by 50-RACE or
RNase protection assays.17 Surprisingly, they also observed that
an effective promoter activity was present 55 base pairs down-
stream of the identified TSS, suggesting that this proximal pro-
moter element may be important for GARS expression. In our
study, we confirmed this assumption by identifying 2 shorter
mRNA isoforms in 6 different adult tissues (heart, brain, bone
marrow, muscle, spleen and liver). These two mRNA isoforms
(mRNA1 and mRNA2) both contained AUGmito and AUGcyto.
Yet, the longer 50-UTR (mRNA1) contained only 90 nucleotides
upstream of AUGmito and a unique additional AUG (AUG0).
Translation of the shorter mRNA2 produces both the mitochon-
drial and the cytosolic GARS, suggesting a leaky scanning mecha-
nism,29,30 whereas the longer mRNA1 produces only the
cytosolic GARS (Fig. 2B). Both mRNAs were found in the
DBTSS,18 however their relative abundances (Fig. S2) did not
allow determining any tissue specific expression profile.
Further analysis of mRNA1 identified the presence of an IRES
structure. Indeed, although the mature mRNA1 (like other cellu-
lar IRESs) contains a 50-cap structure, it drives cap-independent
translation as expected for functional IRESs. The GARS IRES
activity is substantial, it is about 70 % of the vascular endothelial
growth factor and type 1 collagen-inducible protein (VCIP)
IRES activity (Fig. 5). Since Vcip is the most efficient IRES ele-
ment previously characterized (Licursi et al., 2011), GARS IRES
is more efficient than most of the viral and cellular IRES identi-
fied today.
The complexity of the initiation mechanism that characterizes
mRNA1 is further increased by the presence of a short uORF ini-
tiating at AUG0 encoding a putative 32 residue peptide. Interest-
ingly, this particular organization of the 50-UTR is conserved in
all the mammalian genes encoding GARS (Fig. 1B). The intro-
duction of a frameshift mutation between AUG0 and AUGmito
showed that AUG0 is the only initiator codon used to initiate
mRNA1 translation and that the peptide is potentially produced.
The peptide sequence is not strictly conserved between mam-
mals, however they all are proline and arginine rich. It is difficult
to speculate about its hypothetical function since this peptide
was not detectable by mass spectrometry (neither in cell extracts,
nor in cell culture supernatants), due to its size, low abundance
or rapid degradation in the cell. The presence of such a uORF
usually reduces the translation efficiency of the downstream ORF
(reviewed in).31 Indeed, in mRNA1, because the uORF sequence
covers AUGmito, presumed translation of this peptide specifically
hinders the production of the mitochondrial GARS. In contrast,
uORF translation terminates before AUGcyto, allowing transla-
tion of the cytosolic GARS by reinitiating at the AUG directly
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downstream of the stop codon.32 Efficient reinitiation commonly
occurs after translation of short ORFs and can be modulated in
response to environmental changes.33 Moreover, genome wide
bioinformatic analyses show that >45% of mammalian mRNAs
contain at least one uORF,31 and they are frequently translated.34
We cannot exclude that mRNA1 sequence can occasionally be
used for cap-dependent initiation, even if the short 50-UTR
upstream of AUG0 does not support this option. Moreover,
mRNA1 is highly conserved among mammals (Fig. 1B), the
mouse sequence being the most divergent. Still, the mouse IRES
domain shows the same activity as the human IRES domain
(Fig. 5C), indicating that not only the sequence, but also the
function of this 50 domain is conserved in mammals.
Even more striking is the specific colocalization of the
mRNA1 GARS product and ER-bound ribosomes (Fig. 6).
There is increasing evidence that many mRNAs encoding
cytosolic proteins are zip-coded to the ER for localized transla-
tion,35-37 although clear RNA motifs have not yet been identi-
fied. Using HEK297 cell fractionation and ribosome profiling,
David and coworkers performed a genomic survey of the subcel-
lular organization of mRNA translation.38 Interestingly, in their
study, 21% of mRNAs encoding GARS are bound to the ER;
yet, 33% of GARS mRNAs were more heavily loaded with ER-
bound ribosomes, indicating that this mRNA is preferentially
decoded at the ER. In the present study both GARS mRNA iso-
forms, mRNA1 and mRNA2 bind the ER (Fig. S5), thus sharing
a common targeting signal. However, only the IRES containing
mRNA1 is translated locally. It suggests that (i) GARS mRNA
targeting to ER-bound ribosomes is driven by the IRES function
of mRNA1 and (ii) this local translation may modulate GARS
expression. These results provide evidence that subdividing
mRNA2 and mRNA1 translation between the cytosol and the
ER respectively may control the post-transcriptional regulation
of GARS expression.
IRES domains are found in several mRNAs encoding den-
dritic proteins, including activity-regulated cytoskeletal protein,
the a subunit of calcium-calmodulin-dependent kinase II.39
Likewise, all studies on CMT type 2D converge toward a peculiar
expression and function of GARS in peripheral motor and sen-
sory neurons.5-7,9,10 However, it cannot be deduced from the
present study that GARS IRES-containing mRNA1 modulates
neurotoxicity of CMT mutants. Indeed, the absence of the IRES
sequence in invertebrate GARS genes does not prevent GARS-
associated CMT in Drosophila.40 This implies that IRES depen-
dent expression of GARS is not involved in the mechanism
responsible for CMT or that GARS translation is regulated via
an alternative mechanism in Drosophila. In fact, post-transcrip-
tional regulatory mechanisms that control aaRSs expression are
not conserved among aaRSs or in evolution.41
Many proteins encoded by IRES containing mRNAs also play
important roles in cell survival, proliferation, cell cycle and angio-
genesis, all processes that are important in cancer initiation and
progression.24,25 In mammals, Park and collaborators showed
that upon Fas-ligand binding, macrophages (human U937 and
mouse RAW264.7 cell lines) release GARS with anti-tumor
activities,13 suggesting that GARS expression/secretion controls
tumorogenesis. In this particular context, could the mRNA1-
driven translation at the ER trigger the secretion of a specific
extracellular GARS pool? Could it also trigger the secretion of
antigenic GARS engendering autoantibodies in the blood of
polymyositis and dermatomyositis patients?.42,43
This work shows that the 50-extremity of GARS mRNA1
is the site of intricate regulatory mechanisms connecting cap-
independent translational initiation and subcellular localiza-
tion of human GARS (summarized in Fig. 7). Such complex-
ity matches the range of uncovered moonlighting activities
for mammalian GARS connected with tissue-specific expres-
sion or extracellular localization.4,13,14 By exploiting the dif-
ferential translation activities and localization of mRNA1 and
mRNA2, the cell may control the level of GARS synthesis.
In this context, a fraction of GARS specifically translated at
the ER would influence cellular responses distal to the cell
cytosol. An alignment-based structural model of this IRES
sequence gives a rough idea of its structure. However, since
cellular IRESs do not share any common structural motif,44
Figure 7. Suggested models. Summary of GARS expression from mRNA1
and mRNA2 isoforms: mRNA2 codes both the mitochondrial (red MTS)
and the cytosolic GARSs using a leaky scanning mechanism. Only 2 initia-
tion codons are recognized in mRNA1, due to a uORF containing an IRES,
which hinders mitochondrial GARS synthesis. Translation initiation at
AUG0 leads (i) to the synthesis of a short peptide (green) and (ii) to the
subsequent reinitiation at AUGcyto, allowing translation of GARS on ER-
bound ribosomes (blue) and its subsequent diffusion in the cytosol.
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it is difficult to draw a model for translation initiation of
mRNA1. Further studies to understand the dynamics of this
IRES structure will be decisive to comprehend both how this
IRES captures the translation machinery to initiate at AUG0
and how it drives reinitiation at AUGcyto. Could disequilib-
rium between mRNA1 and mRNA2 concentrations affect the
ER/cytoplasmic or the mitochondrial GARSs specifically in
different cell types and affect some alternative function?
Could such an imbalance disturb GARS expression and result
in sick cells or GARS secretion? Because IRES structures may
respond to changing cellular conditions, it is essential now to
identify IRES trans-acting factors involved in mRNA1 trans-
lation to get information about the role of this specific
GARS.
Materials and Methods
RNA ligase-mediated rapid amplification of cDNA
ends (RLM-RACE)
Identification of GARS mRNA 50-and 30-UTRs was per-
formed using the First Choice RLM-RACE kit (Ambion, Life
Technologies) according to the manufacturer’s instructions.
Experiments were performed with 10 mg of highly pure total
RNA from 6 different tissues (liver, spinal cord, brain, skeletal
muscle, heart and spleen, purchased from Ambion).
For 50-RLM-RACE, RNAs were first decapped (as appropri-
ate), ligated to a 50-adaptor and reverse transcribed using a spe-
cific reverse primer 50-TTCCTCGATTGTCTCTTTTTT-
ACCAGTCTCTTGC-30, hybridizing between nucleotides (nt)
2184 and 2216 at the very end of the predicted mitochondrial
GARS ORF sequence. The resulting cDNAs were then subjected
to 2 nested PCRs in the presence of 5% DMSO. PCRs were per-
formed with 2 primers complementary to the 50-adaptor
sequence and 2 nested primers hybridizing the mitochondrial
GARS ORF sequence: outer primer 50-CTCCATTTTT-
TACGTCTTTCA-CCATGAAGTCAGC-30 (nt 595 to 628), inner
primer 50-GGGCTGTAACGCCAGCTCCT-TTGCTTCCAGAA
CCCTC-30 (nt 306 to 342).
Alternatively the 30-RLM-RACE was performed on complete
cDNAs reverse transcribed using a primer hybridizing mRNA
polyA tails and containing a 30-adaptor sequence. PCRs were per-
formed with 2 primers complementary to the 30-adaptor
sequence and 2 nested primers hybridizing the GARS ORF
sequence: outer primer 50-ACTTTGACACAGTGAACA-
AGAC-30 (nt 2018-2039) and inner primer 50-AGCATAGTC-
CAAGACCTAGCCAATGG-30 (nt 2110-2135).
PCR-amplified fragments were cloned into the pDrive clon-
ing vector (PCR cloning kit, Qiagen) and sequenced.
Construction of GARS mammalian expression vectors
GARS mRNA sequences were introduced into a modified
pcDNA3.1 vector for expression. In order to transcribe mRNAs
beginning with their exact 50-extremity, the “extra” sequence
present between the pcDNA3.1 transcription start site and the
KpnI restriction site was removed by mutagenesis (Phusion
Site-Directed Mutagenesis Kit, Thermo Scientific). The sequence
of the GARS ORF was generated by RT-PCR from HeLa cell
total RNA, fused to a C-terminal V5 epitope sequence and intro-
duced in the modified pcDNA3.1 between the KpnI and XbaI
restriction sites. Then both 50-UTR sequences were PCR ampli-
fied from brain cDNA (Ambion) and introduced between the
KpnI restriction site and the unique internal NheI restriction site
present at nt 205 in the mitochondrial GARS ORF. Mutants
were generated by replacing each putative ATG initiator codon
by the ATA sequence (Phusion Site-Directed Mutagenesis Kit).
A 50 stable hairpin structure.19 was introduced at the KpnI site
using 2 overlapping primers: 50-AATTGGTACCTTTG-
CAAAAAGCTCCACCACGGCCCAAGCTTGGGC-30 and 50-
TTA-AGGTACCAAGCTCCACCACGGCCCAAGCTTGGG-
30.
Bicistronic vectors pRF and pRVcipF were a kind gift from
Catherine Schuster, described previously.20 Briefly, pRF con-
tains 2 ORFs, the first one coding for the Renilla luciferase
and the second for the Firefly luciferase. Renilla luciferase is
expressed constitutively (cap-dependant translation), while
Firefly is expressed only if an IRES sequence is introduced in
the intercistronic region. The human mRNA1 50-end
sequence and different variants as well as the mouse mRNA1
sequence were inserted in the intercistronic region between
EcoRI and NcoI to obtain the pRmRNA1F vector and the
mRNA1 structure deletants. pRF, pRVcipF and pRmRNA1F
promotorless constructs were created by excision of the SV40
promoter (between SmaI and EcoRV sites).
Cell culture and transfection
COS-7 cells were cultured in DMEM GlutaMAX growth
medium (Life Technologies) containing 4,5 mg/L glucose,
50 U/mL penicillin, 50 mg/mL streptomycin and 10% fetal calf
serum. Cells were grown at 37 C with 5% CO2.
Twenty-four hours prior to transfection COS-7 cells were
seeded into 6 (or 12) well plates, at a density of 2.105 (or
105) cells per well and cells were then transfected with 100
(or 50 ng) of pcDNA3.1 (or pRF) constructs, using the
Nanofectin transfection reagent according to the man-
ufacturer’s instructions (PAA labs). After 24 hours incuba-
tion, cells were washed with PBS (Life Technologies) and
collected for further investigations.
Immunostaining
For immunolocalization assays, cells were seeded directly on
coverslips treated with 10 mg/cm2 collagen type I (BD Biosci-
ence). Twenty-four hours after transfection, mitochondria were
labeled with 50 nM MitoTracker Orange CMTMRos
(Mitochondrion Selective Probe from Life Technologies) for
30 min at 37 C. When needed, extraction of free cytoplasmic
proteins was performed in the presence of 25 mg/mL digitonin
(Sigma-Aldrich) for 10 minutes on ice. Cells were then washed
twice in PBS, fixed for 10 min with 4% paraformaldehyde (PFA)
and permeabilized in ice-cold methanol for 5 minutes. Cells were
washed with PBS and blocked in 3% BSA (Euromedex) for one
hour.
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Immunostaining of GARS was performed with FITC-conju-
gated mouse anti-V5 monoclonal antibody from Life Technolo-
gies (1:500) at 37 C for 2 hours. Ribosomes were labeled first
under the same conditions with rabbit monoclonal anti-S6 ribo-
somal protein antibody (Pierce) and further detected with
TRITC-conjugated anti-rabbit antibody (40 min at 37 C).
Slides were counterstained with DAPI (Sigma-Aldrich), mounted
in anti-fading solution and visualized under confocal laser scan-
ning microscope (Zeiss LSM 780 Confocal system, Carl Zeiss,
G€ottingen, Germany). The resulting images were analyzed using
Image J Software.
Western blot
Twenty-four hours after transfection, COS-7 cells were incu-
bated in lysis buffer (Promega) for 15 min at RT and the protein
concentration was measured using the Bradford protein assay
reagent (Bio-Rad). Equal quantities of total protein were sepa-
rated on 10% SDS-PAGE and transferred to PVDF membrane
(Bio-Rad). The membrane was blocked for 1 hour in 1X TBS
containing 0.5% Tween20, 3% non-fat dry milk and then incu-
bated with (i) mouse anti-V5 monoclonal antibody HRP–conju-
gated (1:5000; Life Technologies) for 2 hours, (ii) rabbit anti-
firefly luciferase polyclonal (1:5000; Pierce) for 1 hour, or (iii)
mouse monoclonal anti-ßActin (1:10000; Sigma-Aldrich) for
1 hour. Secondary sheep anti-mouse antibody HRP–conjugated
was from GE Healthcare and goat anti-rabbit HRP–conjugated
from Bio-Rad. All incubations were carried out at room
temperature.
Subcellular fractionation
ER fractions were isolated as described.45 Cells (30.106) were
transfected with 5 mg of pCDNA3.1(Mock), pCDNA3.1-
mRNA1 or pCDNA3.1-mRNA2. With this protocol, ER and
mitochondria were efficiently separated on sucrose gradients. For
Western blot analysis, 4 to 5 mg of proteins were probed with
anti-P450 cytochrome oxidase (Genetex), anti-GARS (Abcam)
and anti-V5 antibodies. For RT-PCR, RNA samples were puri-
fied using the NucleoSpin RNA kit (Macherey-Nagel), following
the manufacturer’s protocol. Reverse transcription (RT) was per-
formed in 20 ml reactionswith 200 ng RNA and 100 U M-MLV
reverse transcriptase (Ambion). PCR were carried out on 2 ml of
RT reaction. Fractionation experiments were performed in 4 dif-
ferent conditions: CEDTA/Ccycloheximide (CHX), CEDTA/-
CHX, -EDTA/CCHX and -EDTA/CHX. In the absence of
EDTA, the ER fraction is still contaminated with GARS.
Luciferase activity
Assays were conducted as indicated in the dual luciferase
reporter assay system manual (Promega, France) and error bars
were calculated from 3 independent experiments.
In vitro transcription of GARS mRNA and
in vitro translation
The V5 epitope was replaced by the sequence corresponding
to the 30-UTR of the GARS mRNA, and inserted immediately
downstream of the GARS constructs (XbaI and XhoI). The T7
RNA polymerase promoter and a polyA tail (40 As) were then
introduced by PCR at the 50- and 30-ends of each DNA template,
respectively. In vitro transcription was performed in reaction mix-
tures containing 40 mM Tris-HCl pH 8.1 (37C), 22 mM
MgCl2, 5 mM dithioerythritol, 0.1 mM spermidine, 4 mM
ATP, CTP, and UTP, 1 mM GTP, 2 mM 30-O-Me-m7G(50)
ppp(50)G [m7G] cap structure analog (BioLabs), 40 ng/mL
DNA template and 5 mg/mL T7 RNA polymerase. Transcrip-
tion mixtures were incubated for 2 h at 37C and reactions were
stopped by acidic phenol/chloroform extraction. RNA transcripts
were purified on Nap5 columns (GE-Healthcare) to remove non-
incorporated ribonucleotides, ethanol precipitated, and quanti-
fied on a NanoDrop ND-1000 spectrophotometer. For cap-
dependant/independant in vitro translation assays, mRNAs were
synthetized in the presence of 10 mM 30-O-Me-m7G(50)ppp(50)
G [m7G] or G(50)ppp(50)A [Ap3G] cap structure analogs
(BioLabs).
In vitro translation reactions were carried out with 5 nM
mRNA and 10 mCi [35S] methionine, in rabbit reticulocytes or
wheat germ extract from Promega, according to the man-
ufacturer’s instructions, for 60 minutes at 30C or for 2 hours at
25 C, respectively. Translated proteins were further analyzed by
10% SDS-PAGE, followed by autoradiography and
quantification.
RT-PCR analysis of pRF constructs
Twenty-four hours after transfection, total RNA was
extracted from transfected COS-7 cells using the TRI
Reagent! Protocol (Sigma-Aldrich). Extracted RNA was
treated with DNaseI: 10 mg of RNA were incubated in the
presence of 5U of DNaseI (Sigma-Aldrich) for 40 minutes at
37C. DNaseI-treated RNA (0.5 mg) was reverse transcribed
for 1 hour at 42 C, using the first strand cDNA synthesis
kit (GE Healthcare) following the manufacturer’s protocol.
PCR reactions were performed with the Phusion Taq poly-
merase (Thermo-Scientific) on 1 mL of reverse transcription
product in the presence of 3% DMSO.
Multi-alignment-based structure
A consensus structure was deduced from all mRNA1 mamma-
lian sequences using the structural aligner LocARNA.47 This
structure was re-evaluated and curated with the last version of the
graphical tool Assemble.48
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